Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Electron Transport Chain: Complex I and II

Electron Transport Chain: Complex I and II

The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...

Inhibition of Cdk Activity

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Rosamine derivatives of <i>o</i>-aminothiophenol-triacetate (S-APTRA): a new class of selective fluorescent sensors for Zn<sup>2</sup>.

Organic & biomolecular chemistry·2026

Same author

Multiple forms of protein-protein and DNA binding are exhibited by BrxC from the BREX phage restriction system.

Nucleic acids research·2026

Same author

Ribosomal RNA cleavage by the previously unidentified RelS-RelI toxin-antitoxin system controls growth of Mycobacterium tuberculosis.

Nucleic acids research·2026

Same author

DNA modifications of Durham Collection phages and promiscuity of GmrSD-family Type IV restriction enzyme BrxU.

Applied and environmental microbiology·2026

Same author

Protein binding regulates complex configuration: comparative analysis of three dynamically racemic europium(iii) complexes.

RSC advances·2026

Same author

Population Genomics of a Cosmopolitan Weed Provides Insights Into Its Local Adaptation and Recent Demographic History.

Molecular ecology·2026

Search research articles

Related Experiment Video

Updated: Dec 20, 2025

Assays for Validating Histone Acetyltransferase Inhibitors

Assays for Validating Histone Acetyltransferase Inhibitors

Published on: August 6, 2020

Anticancer Ruthenium Complexes with HDAC Isoform Selectivity.

Jasmine M Cross¹, Tim R Blower², Alexander D H Kingdon¹

¹Department of Chemistry, Durham University, Lower Mountjoy, South Road, Durham DH1 3LE, UK.

Molecules (Basel, Switzerland)

|May 28, 2020

Summary

This summary is machine-generated.

Piano stool Ruthenium (Ru) complexes show promise as histone deacetylase (HDAC) inhibitors for cancer therapy. Modifying the capping arene on these Ru complexes can tune their selectivity across different HDAC isoforms, potentially reducing side effects.

Keywords:

histone deacetylase inhibitors ruthenium in medicine selective enzyme inhibition

More Related Videos

Simultaneous Measurement of HDAC1 and HDAC6 Activity in HeLa Cells Using UHPLC-MS

Simultaneous Measurement of HDAC1 and HDAC6 Activity in HeLa Cells Using UHPLC-MS

Published on: August 10, 2017

Synthesis and Evaluation of a Ruthenium-based Mitochondrial Calcium Uptake Inhibitor

Synthesis and Evaluation of a Ruthenium-based Mitochondrial Calcium Uptake Inhibitor

Published on: October 26, 2017

Related Experiment Videos

Last Updated: Dec 20, 2025

Assays for Validating Histone Acetyltransferase Inhibitors

Assays for Validating Histone Acetyltransferase Inhibitors

Published on: August 6, 2020

Simultaneous Measurement of HDAC1 and HDAC6 Activity in HeLa Cells Using UHPLC-MS

Simultaneous Measurement of HDAC1 and HDAC6 Activity in HeLa Cells Using UHPLC-MS

Published on: August 10, 2017

Synthesis and Evaluation of a Ruthenium-based Mitochondrial Calcium Uptake Inhibitor

Synthesis and Evaluation of a Ruthenium-based Mitochondrial Calcium Uptake Inhibitor

Published on: October 26, 2017

Area of Science:

Biochemistry
Medicinal Chemistry
Cancer Biology

Background:

Histone deacetylases (HDACs) are crucial targets in cancer therapy, with several inhibitors approved for clinical use.
Current HDAC inhibitors often lack isoform selectivity, leading to potential adverse effects.
Developing selective HDAC inhibitors is essential for improving cancer treatment efficacy and patient safety.

Purpose of the Study:

To investigate piano stool Ruthenium (Ru) complexes as novel histone deacetylase (HDAC) inhibitors.
To explore the impact of varying capping arene ligands on the isoform selectivity of Ru-based HDAC inhibitors.
To assess the potential of these complexes in developing more targeted cancer therapies.

Main Methods:

Synthesis and characterization of a series of piano stool Ru complexes with diverse capping arenes.
In vitro enzymatic assays to evaluate the inhibitory activity of Ru complexes against various HDAC isoforms.
Structure-activity relationship analysis to correlate ligand modifications with HDAC isoform selectivity.

Main Results:

Piano stool Ru complexes demonstrate significant HDAC inhibitory activity.
Systematic variation of the capping arene ligand resulted in differential selectivity across HDAC isoforms.
Specific Ru complexes exhibited enhanced selectivity for certain HDAC targets compared to others.

Conclusions:

Piano stool Ru complexes represent a promising new class of HDAC inhibitors for cancer treatment.
Ligand design offers a viable strategy to achieve isoform-selective HDAC inhibition with Ru complexes.
Further development of these selective Ru-based inhibitors could lead to improved cancer therapeutics with reduced side effects.